hotspot -WSS

hotspot

author：leisure time 2025-09-28 22:52:51 - browse：7717

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Drug repurposing or repositioning? The language matters

explore

WSS

Senate panel puts off hardest PBM reforms for another day

What it's like to live with paralysis for one psychologist

In Memoriam: Notable people who died in 2023

What it's like to live with paralysis for one psychologist

Why patients can’t get everything they want on drug pricing

'Investigate these claims': UFO transparency at center of House hearing

knowledge

hotspot

entertainment

How one medical school became remarkably diverse

Search called off for baby washed away in Pennsylvania flash flood

After affirmative action ruling, medical educators look to 'holistic review'

New air purifier tech could be key to improving indoor air quality

The cancer drug shortage isn’t new — and neither are the solutions

Moonlake's readout produced a cash windfall. Risks remain

Medical records are filled with copy

Bright Health sells Medicare Advantage business to Molina

Malaria cases in Florida and Texas: Here’s what you need to know

United colonoscopy coverage change 'may cost lives,' doctors say

focus

'Investigate these claims': UFO transparency at center of House hearing

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UHS says company favors patients whose insurance pays more

Former reverend arrested for allegedly killing 8

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

knowledge

hotspot

explore

focus